Brain metastasis of hepatocellular carcinoma: A case report and review of the literature

Tunç, Bilge; Filik, Levent; Tezer-Filik, Irsel; Sahin, Burhan

doi:10.3748/wjg.v10.i11.1688

Cited by 31 publications

(26 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lymph node metastases, 45 bone metastases, 46,47 brain metastases, 48,49 and other soft tissue metastases 50 from HCC have been treated with palliative RT with good symptom control. Pain relief from bone metastases was observed in 73% to 83% of patients in 2 of the largest series published to date, 46,47 emphasizing the radiation responsiveness of HCC.…”

Section: Palliative Rtmentioning

confidence: 99%

Radiation therapy for hepatocellular carcinoma

Hawkins

Dawson

2006

Cancer

221

171

View full text Add to dashboard Cite

Technologic advances have provided the means to deliver tumoricidal doses of radiation therapy (RT) to patients with unresectable hepatocellular carcinoma (HCC) while avoiding critical normal tissues, providing the opportunity to use RT for curative intent treatment of HCC. For the current report, the expanded role of external beam RT in the setting of HCC from palliation to cure was reviewed. A systematic literature search was undertaken using the MEDLINE data base and secondary references to identify peer-reviewed, English-language articles that re- control response rates ranged from 40% to 90%, and the median survival ranges from 10 months to 25 months. For patients with HCC who had portal vein thrombus, the median survival after RT to treat the thrombus and/or the hepatic tumor with or without TACE ranged from 5.3 months to 9.7 months. Although outcomes after high-dose conformal RT for liver-confined HCC were excellent, the potential survival benefit of RT should be tested in randomized controlled trials that require international collaboration.

show abstract

Section: Palliative Rtmentioning

confidence: 99%

Radiation therapy for hepatocellular carcinoma

Hawkins

Dawson

2006

Cancer

221

171

View full text Add to dashboard Cite

show abstract

“…The interval from diagnosis of the primary tumor to development of BM is reported to be 2-54 months [66,76]. Cases in which the initial diagnosis of HCC is made by establishing BM as well as those with long intervals of up to 17 years are also reported [69].…”

Section: Management and Therapymentioning

confidence: 92%

“…Post mortem incidence is higher and ranges from 1.7% to 5% [66,[73][74][75]. Systemic metastatic disease favors development of BM [66,[70][71][72]76]. Additional lung metastases are present in 78% of patients with BM [72].…”

Section: Hepatocellular Carcinomamentioning

confidence: 99%

“…In these regions, it constitutes one of the most frequent malignancies due to the high prevalence of hepatitis B and C. Men are 4.8 times more likely to be affected than women [57,66,69,70]. Information regarding BM from HCC is based on case reports [65,67,68,[71][72][73][74][75][76][77] and Case report with no patient series c One patient's therapy was not specified small case studies [57,66,[69][70][71]78]. The Japanese tumor register estimates that 1.2% of all BM originate from HCC [57,74].…”

Section: Hepatocellular Carcinomamentioning

confidence: 99%

See 1 more Smart Citation

Modern management of rare brain metastases in adults

et al. 2011

View full text Add to dashboard Cite

Brain metastases (BM) represent the main cause of intracranial neoplasms in adults, while being relatively less common in children. Today, better treatment options of the primary malignancy lead to higher remission rates as well as prolonged stable clinical conditions. This may in part explain the increased incidence of BM. Morbidity and mortality rates in patients with malignancies deteriorate significantly in cases of metastatic involvement of the central nervous system. Nowadays, especially modern management using surgical, medical, and radiotherapeutic options for treatment of BM tends to improve survival rates and enhance quality of life. Nonetheless, almost all treatment options are considered as palliative. In this review, we outline current knowledge of the incidence, diagnostic facilities, and therapeutic management of rare BM, with consideration of the basic aspects of the primary malignancy.

show abstract

“…Skull and intracranial metastases from hepatocellular carcinoma (HCC) have been rarely reported 2,5,9,14) . Epidural hematoma (EDH), subdural hematomas (SDH), and intracerebral hemorrhage from skull metastasis of HCC are also extremely rare 5) .…”

Section: Introductionmentioning

confidence: 99%

Spontaneous Epidural Hematoma from Skull Base Metastasis of Hepatocellular Carcinoma

Woo

Kim

Cho

et al. 2010

J Korean Neurosurg Soc

View full text Add to dashboard Cite

We report a case of an acute spontaneous epidural hematoma (EDH) due to skull base metastasis in a 46-year-old male patient with hepatocellular carcinoma (HCC). The patient presented with the acute onset of severe headache followed by unconsciousness, and computed tomography showed a large EDH in the right temporal and parietal lobes with midline shift. Emergency evacuation of the EDH was performed, and the hemorrhage was determined to be secondary to skull base metastasis of HCC. KEY WORDS : Epidural hematoma˙ Skull base metastasis˙ Hepatocellular carcinoma

show abstract

Brain metastasis of hepatocellular carcinoma: A case report and review of the literature

Cited by 31 publications

References 10 publications

Radiation therapy for hepatocellular carcinoma

Radiation therapy for hepatocellular carcinoma

Modern management of rare brain metastases in adults

Spontaneous Epidural Hematoma from Skull Base Metastasis of Hepatocellular Carcinoma

Contact Info

Product

Resources

About